AUDIT study. Evidence of global undertreatment of dyslipidaemia in patients with type 2 diabetes mellitus

Lawrence A. Leiter, D. John Betteridge, Antonio R. Chacra, Alan Chait, Eleuterio Ferrannini, Steven M. Haffner, Takashi Kadowaki, Jaakko Tuomilehto, Paul Zimmet, Connie B. Newman, Judith Hey-Hadavi, Caroline Walkinshaw

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The Analysis and Understanding of Diabetes and Dyslipidaemia: Improving Treatment (AUDIT) study was a confidential, web-based, cross-sectional survey involving 2,043 diabetes specialists in 50 countries. The study investigated the attitudes of physicians specialising in the treatment of patients with type 2 diabetes mellitus towards the management of dyslipidaemia and other cardiovascular risk factors in these patients. Physicians reported obtaining lipid profiles in 91% of patients with type 2 diabetes and estimated that 62% of type 2 diabetic patients have dyslipidaemia. Across all regions, stated low-density lipoprotein cholesterol (LDL-C), triglyceride and total cholesterol targets were lower for type 2 diabetic patients with than without cardiovascular disease (CVD). Fewer physicians reported having an LDL-C target of ≤ 2.6 mmol/L (≤ 100 mg/dL) for patients without CVD (59%) than with CVD (85%). Physicians reported that 54% of patients achieve LDL-C targets, with significantly more estimated to achieve their LDL-C goal in North America (69%) than in any other region (43-61%; p<0.001). When setting targets, 58% of physicians stated that they were most influenced by lipid management guidelines, although a large proportion of physicians from Eastern Europe (54%) and Africa/Middle East (50%) cited a personal read of the literature. Patient compliance was the most commonly perceived barrier to lipid goal attainment in most regions (42-61%); financial constraints were cited most often in South America (76%), Africa/Middle East (65%) and Eastern Europe (63%). The AUDIT study revealed a disparity between lipid screening and control in type 2 diabetic patients. Physicians reported that they treated patients without CVD less intensively than patients with CVD, suggesting that type 2 diabetes was not widely considered a coronary heart disease risk equivalent. A reassessment of guideline implementation is needed for physicians worldwide to improve lipid control to decrease cardiovascular risk in type 2 diabetes.

Original languageEnglish
Pages (from-to)31-40
Number of pages10
JournalBritish Journal of Diabetes and Vascular Disease
Volume6
Issue number1
DOIs
Publication statusPublished - 1 Jan 2006
Externally publishedYes

Keywords

  • Cardiovascular diseases
  • Guidelines
  • Hypercholesterolaemia
  • Lipids
  • Risk factors
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this